Glenmark Pharmaceuticals LLtd. Q4 FY25 results:

- Net Profit: Glenmark Pharma swung to a net profit of ₹4.7 crore in Q4 FY25 from a loss of ₹1,218 crore in the same period last year. - Annual PAT: The company posted a consolidated adjusted profit after tax (PAT) of ₹1,389.4 crore for FY25, with revenues reaching ₹13,321.7 crore, a 12.8% year-on-year increase. - Revenue Growth: Revenue for Q4 FY25 stood at ₹3,256 crore, up 6.3% from ₹3,063 crore in Q4 FY24. EBITDA margin improved to 17.2%, with an 11.2% increase in EBITDA to ₹561 crore.